Related Experiment Video
Updated: May 2, 2026

Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma
Shephali Bhatnagar1, Howard Chertkow2, Hyman M Schipper3
1Advanced Genomic Technology, LLC Louisville, KY, USA.
Abstract:
Circulating microRNAs, present either in the cellular component, peripheral blood mononuclear cells (PBMC), or in cell-free plasma, have emerged as biomarkers for age-dependent systemic, disease-associated changes in many organs. Previously, we have shown that microRNA (miR)-34a is increased in circulating PBMC of Alzheimer's disease (AD) patients. In the present study, we show that this microRNA's sister, miR-34c, exhibits even greater increase in both cellular and plasma components of AD circulating blood samples, compared to normal age-matched controls. Statistical analysis shows the accuracy of levels of miR-34c assayed by receiver operating characteristic (ROC) analysis: the area under the curve is 0.99 (p < 0.0001) and the 95% confidence level extends from 0.97 to 1. Pearson correlation between miR-34c levels and mild and moderate AD, as defined by the mini-mental state examination (MMSE), shows an r-value of -0.7, suggesting a relatively strong inverse relationship between the two parameters. These data show that plasma levels of microRNA 34c are much more prominent in AD than those of its sister, miR-34a, or than its own level in PBMC. Transfection studies show that miR-34c, as does its sister miR-34a, represses the expression of several selected genes involved in cell survival and oxidative defense pathways, such as Bcl2, SIRT1, and others, in cultured cells. Taken together, our results indicate that increased levels of miR-34c in both PBMC and plasma may reflect changes in circulating blood samples in AD patients, compared to age-matched normal controls.
Insights
MicroRNA 34c is significantly elevated in the blood of Alzheimer's disease (AD) patients, serving as a potential biomarker. Higher miR-34c levels correlate with AD severity, impacting cell survival genes.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Circulating microRNAs (miRNAs) are emerging biomarkers for age-related diseases.
- Previous research identified increased miR-34a in Alzheimer's disease (AD) patients' peripheral blood mononuclear cells (PBMCs).
Purpose of the Study:
- To investigate the role of miR-34c as a potential biomarker in Alzheimer's disease.
- To compare the levels of miR-34c with miR-34a in AD patients' blood samples.
Main Methods:
- Quantification of miR-34c levels in plasma and PBMCs from AD patients and age-matched controls.
- Statistical analysis including Receiver Operating Characteristic (ROC) curve analysis and Pearson correlation.
- Gene expression analysis using transfection studies to assess miR-34c's effect on target genes.
Main Results:
- miR-34c showed a significantly greater increase in both plasma and PBMCs of AD patients compared to controls.
- ROC analysis demonstrated high accuracy for miR-34c as an AD biomarker (AUC = 0.99).
- A strong inverse correlation (r = -0.7) was observed between miR-34c levels and AD severity (MMSE scores).
- miR-34c, similar to miR-34a, represses genes involved in cell survival and oxidative defense (e.g., Bcl2, SIRT1).
Conclusions:
- Plasma miR-34c levels are a more prominent indicator in AD than miR-34a or miR-34c in PBMCs.
- Elevated miR-34c in blood may reflect systemic changes associated with Alzheimer's disease.
- miR-34c represents a promising circulating biomarker for Alzheimer's disease diagnosis and progression.
Related Concept Videos
MicroRNAs
MicroRNAs
Alzheimer Disease ll: Pathophysiology

